Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Operable Head and Neck Cancer
NCT02593929Phase 1Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Pittsburgh. Primary endpoint: Baseline and/or pharmacodynamic biomarkers of response to ruxolitinib. Planned start Jan 2017; status: withdrawn.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02593929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593929.